Swiss Pediatric Oncology Group Report issue

Academic/Hospital Phase 1 Phase 3

Organization Overview

First Clinical Trial
1998
NCT00003528
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

Swiss Pediatric Oncology Group - Geneva

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fever (Phase 3)

Leukemia (Phase 1)

Neutropenia (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Rhabdomyosarcoma (Phase 3)

Sarcoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6